Last reviewed · How we verify
insulin glulisine, insulin aspart — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
insulin glulisine, insulin aspart (insulin glulisine, insulin aspart) — Profil Institut für Stoffwechselforschung GmbH.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| insulin glulisine, insulin aspart TARGET | insulin glulisine, insulin aspart | Profil Institut für Stoffwechselforschung GmbH | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- insulin glulisine, insulin aspart CI watch — RSS
- insulin glulisine, insulin aspart CI watch — Atom
- insulin glulisine, insulin aspart CI watch — JSON
- insulin glulisine, insulin aspart alone — RSS
Cite this brief
Drug Landscape (2026). insulin glulisine, insulin aspart — Competitive Intelligence Brief. https://druglandscape.com/ci/insulin-glulisine-insulin-aspart. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab